Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Jan 15, 2021 4:10pm EST

Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease

Dec 07, 2020 8:00am EST

Beyond Air® to Participate in the 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020

Nov 19, 2020 8:00am EST

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update

Nov 11, 2020 4:10pm EST

Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn

Nov 11, 2020 7:30am EST

Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Oct 23, 2020 8:00am EDT

Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19

Oct 21, 2020 7:00am EDT

Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR Conference on Tumor Immunology and Immunotherapy

Oct 19, 2020 10:01am EDT

Beyond Air® Presents Data Showing Anti-Coronavirus Activity of Nitric Oxide at the CHEST Annual Meeting 2020

Oct 19, 2020 7:15am EDT

Beyond Air® Presents Pilot Bronchiolitis Data at the CHEST Annual Meeting 2020

Oct 19, 2020 7:00am EDT